论文部分内容阅读
作者报告以遗传工程技术制成的重组体人粒-巨噬细胞集落刺激因子(rGm-CSF)治疗骨髓增生异常综合征(MDS)8例,获得良好效果。病人和方法 8例按 FAB 分类,难治性贫血(RA)1例,难治性贫血伴过多原始细胞(RAEB)3例,难治性贫血伴过多原始细胞向白血病转化(RAEB-T)4例。男6例,女2例,年龄43～79岁。除1例血小板数正常外,其余7例均出现全血细胞减少,6例骨髓原始细胞≥10%。用 rGm-CSF 治疗前,8例均需间断输红细胞,4例每1～2周要输血小板。所有病人估计寿命至少在12周,肝肾功能正常,凝血酶原时间≤1.3倍正常值。
The authors report 8 cases of myelodysplastic syndrome (MDS) treated with recombinant human granulocyte-macrophage colony-stimulating factor (rGm-CSF) made by genetic engineering techniques and achieved good results. Patients and Methods Eight patients were classified according to FAB, including 1 case of refractory anemia (RA), 3 cases of refractory anemia with excess blasts (RAEB), and 1 case of refractory anemia with excess of blast cells to leukemia (RAEB-T ) 4 cases. 6 males and 2 females, aged 43 to 79 years old. In addition to the normal number of platelets in one case, pancytopenia occurred in the remaining seven cases and ≥10% in six bone marrow blasts. Before treatment with rGm-CSF, 8 patients required intermittent transfusion of red blood cells, and 4 transfusion of platelets every 1 to 2 weeks. All patients have an estimated life expectancy of at least 12 weeks, normal liver and kidney function, and prothrombin time ≤ 1.3 times normal.